期刊文献+

人黏蛋白1串联重复区DNA疫苗诱导小鼠的免疫应答 被引量:1

Immune Response Induced by MUC1 VNTR DNA Vaccine in Mice
下载PDF
导出
摘要 目的观察人黏蛋白1串联重复区(MUC1 VNTR)DNA疫苗诱导BALB/c小鼠的体液及细胞免疫应答。方法将含有33个黏蛋白1重复区序列(33m)的重组质粒pVR1012-33m,经肌肉注射免疫BALB/c小鼠,并加强免疫2次,每次100μg,间隔2周,分别以空载体pVR1012和生理盐水为对照。末次免疫后取小鼠血清及脾淋巴细胞,Western blot检测血清抗体特异性,LDH法检测CTL反应活性,MTS/PMS法检测脾淋巴细胞增殖活性。结果重组质粒免疫组小鼠血清中检出了MUC1 VNTR抗原特异性抗体。用重组质粒pVR1012-33m免疫BALB/c小鼠后,在效靶比为100:1和33:1时,可显著地诱导特异性CTL应答。在MUC1 VNTR抗原肽的刺激下,免疫小鼠脾淋巴细胞得到增殖,与空载体和生理盐水对照组相比,差异均有显著意义。结论DNA疫苗pVR1012-33m在BALB/c小鼠体内可诱导特异性细胞免疫和体液免疫应答,为预防、治疗性MUC1 VNTR疫苗的研制提供了一定的实验依据。 Objective To observe the humoral and cellular immune responses induced by MUC1 variable number of tandem repeats,VNTR DNA vaccine in mice. Methods Inject i. m. BALB/c mice with 100 p.g of recombinant plasmid pVR1012-33m contai- ning 33 repeats of MUC1 VNTR for 3 times, at an interval of 2 weeks, using empty vector pVR1012 and physiological saline as control. Collect the sera and spleen lymphocytes of mice after immunization and test for serum antibody specificity by Western blot ,CTL activity by LDH method,and spleen lymphocyte proliferation activity by MTS/PMS method. Results Specific antibody against MUC1 VNTR antigen was detected in sera of mice immunized with recombinant plasmid pVR1012-33m. When the ratio of effector cells to target cells were 100:1 and 33: 1, specific CTL responses were induced in immunized mice significantly. Compared with those immunized with emp- ty vector and physiological saline ,the spleen lymphocythes of mice immunized with recombinant plasmid pVR1012-33m proliferated sig- nificantly. Conclusion Recombinant plasmid pVR1012-33m induced specific cellular and humoral immune responses in mice, which provided experimental basis for the development of prophylactic and therapeutic MUCI VNTR vaccine.
出处 《中国生物制品学杂志》 CAS CSCD 2007年第10期729-732,共4页 Chinese Journal of Biologicals
关键词 黏蛋白l串联重复区 DNA疫苗 细胞免疫 体液免疫 MUC1 VNTR DNA vaccine Cellular immunity Humoral immunity
  • 相关文献

参考文献11

  • 1Nagata T,Aoshi T,Uchijima M,et al.Cytotoxic T-lymphocyte-,and helper T-lymphocyte-oriented DNA vaccination.DNA Cell Biol,2004,23(2):93-106.
  • 2Karsten U,Von Mensdorff-Pouilly S,Goletz S.What makes MUC1 a tumor antigen.Tumour Biol,2005,26(4):217-220.
  • 3Patel KN,Maghami E,Wreesmann VB,et al.MUC1 plays a role in tumor maintenance in aggressive thyroid carcin-omas.Surgery,2005,138(6):994-1001.
  • 4Singh AP,Chauhan SC,Bafna S,et al.Aberrant expression of transmembrane mucins,MUC1 and MUC4,in human prostate carcinomas.Prostate,2006,66(4):421-429.
  • 5Acres B,Limacher JM.MUC1 as a target antigen for cancer immunotherapy.Expert Rev Vaccines,2005,4(4):493-502.
  • 6Soares MM,Mehta V,Finn OJ.Three different vaccines based on the 140-amino acid MUC1 peptide with seven tandemly repeated tumorspecific epitopes elicit distinct immune effector mechanisms in wildtype versus MUC1-transgenic mice with different potential for tumor rejection.J Immunol,2001,166(11):6555-6563.
  • 7Snyder LA,Goletz TJ,Gunn GR,et al.A MUC1/IL-18 DNA vaccine induces anti-tumor immunity and increased surival in MUC1 transgenic mice.Vaccine,2006,24(16):3340-3352.
  • 8Hanisch FG.Design of a MUC1-basnd cancer vaccine.Biochem Soc Trans,2005,33(Pt 4):705-708.
  • 9Mukherjee P,Pathangey LB,Bradley JB,et al.MUC1-specific immune therapy generates a strong anti-tumor response in a MUC1-tolerant colon cancer model.Vaccine,2007,25(9):1607-1618.
  • 10Li Y,Cozzi PJ.MUC1 is a promising therapeutic target for prostate cancer therapy.Curr Cancer Drug Targets,2007,7 (3):259-271.

同被引文献6

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部